ProCE Banner Activity

CE / CME

Why Do We Believe HCV Elimination Is Possible?

Multimedia
Watch and listen as Jordan J. Feld, MD, MPH, and Natasha Martin, DPhil, discuss what makes achieving HCV elimination feasible: targeting at-risk populations, delivering multiple interventions, and personalizing interventions to optimize outcomes by risk group.

Pharmacists : 0.50 contact {hour} ({0.05} CEUs)

Physicians : maximum of 0.50 AMA PRA Category 1 {Credit}

Released: October 24, 2017

Expiration: October 23, 2018

No longer available for credit.

Share

Faculty

Norah Terrault

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Jordan J. Feld

Jordan J. Feld, MD, MPH

Assistant Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Diseases
Sandra Rotman Centre for Global Health
Toronto, Ontario, Canada

Natasha Martin

Natasha Martin, DPhil

Associate Professor
Division of Infectious Diseases and Global Public Health
University of California, San Diego
La Jolla, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify strategies that support HCV elimination efforts in key populations at risk for HCV acquisition

Program Director Disclosure

Program Director

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Gilead Sciences and Merck and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Faculty Disclosure

Primary Author

Jordan J. Feld, MD, MPH

Assistant Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Diseases
Sandra Rotman Centre for Global Health
Toronto, Ontario, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, ContraVir, Gilead Sciences, Janssen, and Merck and funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, and Merck.

Natasha Martin, DPhil

Associate Professor
Division of Infectious Diseases and Global Public Health
University of California, San Diego
La Jolla, California

Natasha Martin, DPhil, has disclosed that she has received consulting fees and funds for research support from Gilead Sciences.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

This educational activity for 0.4 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education (Universal Program Number – JA4008162-9999-18-222-H01-P).

Type of Activity: Knowledge

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 24, 2017, through October 23, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.